Lilly Eli & Co (LLY): Endowment Inc Lilly , 10% owner of Lilly Eli & Co sold 200,000 shares on Apr 8, 2016. The Insider selling transaction was disclosed on Apr 11, 2016 to the Securities and Exchange Commission. The shares were sold at $74.29 per share for a total value of $148578.
Company has been under the radar of several Street Analysts.Eli Lilly and Co is Initiated by Societe Generale to Hold and the brokerage firm has set the Price Target at $78. The Rating was issued on Apr 6, 2016.
Currently the company Insiders own 0.21% of Eli Lilly and Co shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -6.8%.Institutional Investors own 75.5% of Eli Lilly and Co shares.During last six month period, the net percent change held by insiders has seen a change of -1.21%.
Shares of Eli Lilly and Co (LLY) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.44 points or -0.59% at $73.95 with 33,51,100 shares getting traded. Post opening the session at $74.48, the shares hit an intraday low of $73.795 and an intraday high of $74.74 and the price vacillated in this range throughout the day. The company has a market cap of $81,796 M and the number of outstanding shares has been calculated to be 1,10,60,93,490 shares. The 52-week high of Eli Lilly and Co is $92.85 and the 52-week low is $67.88.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.